ACTIVE BIOTECH AB | 5,876 Euro | -0,222 -3,64 % | |
| WKN: A0BLFX ISIN: SE0001137985 Ticker-Symbol: BTPC | Frankfurt | 24.05.13 | 08:07 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 16.05. | EXINI Diagnostics AB: EXINI and Active Biotech present mutual results at US cancer conference | 41 | GlobeNewswire | |
| Lund, Sweden, 2013-05-16 08:50 CEST (GLOBE NEWSWIRE) --
Lund, Sweden, May 16, 2013, EXINI Diagnostics AB (publ), listed on NASDAQ OMX
First North and Active Biotech (NASDAQ OMX NORDIC: ACTI) will present... Mehr lesen zu: EXINI Diagnostics AB: EXINI and Active Biotech present mutual results at US cancer conference | ||||
| 16.05. | Active Biotech: Annual General Meeting of Active Biotech AB | 40 | Thomson Reuters ONE | |
| The Annual General Meeting of Active Biotech was held on May 15, 2013. In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid. In accordance with the... Mehr lesen zu: Active Biotech: Annual General Meeting of Active Biotech AB | ||||
| 16.05. | Active Biotech: New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology research | 42 | Thomson Reuters ONE | |
| Lund, Sweden, May 16, 2013, Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data from two of its oncology projects, the drug candidates tasquinimod for the treatment of prostate cancer and ANYARA... Mehr lesen zu: Active Biotech: New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology research | ||||
| 25.04. | Active Biotech and Ipsen revise drug analysis plan | 2 | StockMarketWire | |
| 25.04. | Active Biotech: Active Biotech AB Interim Report January - March 2013 | 56 | Thomson Reuters ONE | |
| Laquinimod · first patient enrolled in CONCERTO, the third Phase III placebo-controlled study for the treatment of relapsing-remitting multiple sclerosis · data presented at AAN showed reduced disability... Mehr lesen zu: Active Biotech: Active Biotech AB Interim Report January - March 2013 | ||||
| 25.04. | Active Biotech: Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer | 107 | Thomson Reuters ONE | |
| Primary PFS analysis now expected at the same time as first interim overall survival analysis in 2014 Lund (Sweden) and Paris (France), 25 April, 2013, Active Biotech (NASDAQ OMX NORDIC: ACTI)... Mehr lesen zu: Active Biotech: Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancer | ||||
| 25.04. | Active Biotech and Ipsen Update the Analysis Plan for the 10TASQ10 Trial Evaluating Tasquinimod in the Treatment of Prostate Cancer | 36 | Business Wire | |
| Primary PFS Analysis Now Expected at the Same Time as First Interim Overall Survival Analysis in 2014 Regulatory News: Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext:... Mehr lesen zu: Active Biotech and Ipsen Update the Analysis Plan for the 10TASQ10 Trial Evaluating Tasquinimod in the Treatment of Prostate Cancer | ||||
| 15.04. | Active Biotech: Annual Report 2012 Active Biotech AB (publ) | 77 | Thomson Reuters ONE | |
| Active Biotech's Annual Report 2012 (in Swedish) is now available for download at www.activebiotech.com (http://www.activebiotech.com/). The English version will be available within short. The... Mehr lesen zu: Active Biotech: Annual Report 2012 Active Biotech AB (publ) | ||||
| 11.04. | Active Biotech: Active Biotech - Notice of Annual General Meeting of Shareholders | 82 | Thomson Reuters ONE | |
| The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place at 5 p.m. on Wednesday, May 15, 2013, at Edison Park, Emdalavägen 16 in... Mehr lesen zu: Active Biotech: Active Biotech - Notice of Annual General Meeting of Shareholders | ||||
| 28.03. | Active Biotech: Number of shares and votes in Active Biotech | 54 | Thomson Reuters ONE | |
| The number of shares and votes in Active Biotech has changed as a result of the directed new issue to Investor as previously announced. Today, the last trading day of the month, there are in total... Mehr lesen zu: Active Biotech: Number of shares and votes in Active Biotech | ||||
| 21.03. | Active Biotech: EARLY VERSUS DELAYED TREATMENT WITH LAQUINIMOD DEMONSTRATED SIGNIFICANT REDUCTION IN RISK OF DISABILITY PROGRESSION - RESULTS OF THREE-YEAR ALLEGRO STUDY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS | 80 | Thomson Reuters ONE | |
| · Data presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) showed early treatment with laquinimod demonstrated significant benefit in terms of slowing disability... Mehr lesen zu: Active Biotech: EARLY VERSUS DELAYED TREATMENT WITH LAQUINIMOD DEMONSTRATED SIGNIFICANT REDUCTION IN RISK OF DISABILITY PROGRESSION - RESULTS OF THREE-YEAR ALLEGRO STUDY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS | ||||
| 11.03. | Active Biotech, Teva complete first patient enrollment in RRMS drug Phase III study | 6 | Pharma Bus Review | |
| 06.03. | Teva, Active Biotech Announce First Patient Enrollment In CONCERTO Study | 106 | AFX News | |
| PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) and
Active Biotech (ACTI.ST) Wednesday announced enrollment of the first patient in
the CONCERTO study - the third Phase... Mehr lesen zu: Teva, Active Biotech Announce First Patient Enrollment In CONCERTO Study | ||||
| 06.03. | Active Biotech enrols first patient in CONCERTO study | - | StockMarketWire | |
| 06.03. | Active Biotech: FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS | 38 | Thomson Reuters ONE | |
| CONCERTO Study Enrolling Patients Globally to Evaluate Impact of Laquinimod on Disability Progression Jerusalem, Israel and Lund, Sweden, March 6, 2013 - Teva Pharmaceutical Industries Ltd. (NYSE:... Mehr lesen zu: Active Biotech: FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS | ||||
| 06.03. | Active Biotech Rises as Investor AB Buys Stake: Stockholm Mover | 10 | Bloomberg | |
| 06.03. | Investor Subscribes for SEK 270 m. in a Directed New Issue in Active Biotech | 47 | Business Wire | |
| Regulatory News:
Investor (STO:INVEA)(STO:INVEB) (LSE:INU) has entered into an agreement
to subscribe for SEK 270 m. in a directed new issue in Active Biotech... Mehr lesen zu: Investor Subscribes for SEK 270 m. in a Directed New Issue in Active Biotech | ||||
| 06.03. | Active Biotech: Active Biotech raises SEK 270 million through a directed new issue to Investor | 65 | Thomson Reuters ONE | |
| Lund, Sweden, March 6, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today announces that the company's Board of Directors has, based on the 2012 annual general meeting's authorization, resolved... Mehr lesen zu: Active Biotech: Active Biotech raises SEK 270 million through a directed new issue to Investor | ||||
| 14.02. | Active Biotech: Active Biotech AB Year-end report January - December 2012 | 74 | Thomson Reuters ONE | |
| Events for the full year 2012Laquinimod Phase III data presented at the AAN (64th Annual Meeting of the American Academy of Neurology)Application submitted for regulatory approval in the EU,... Mehr lesen zu: Active Biotech: Active Biotech AB Year-end report January - December 2012 | ||||
| 28.01. | Active Biotech: Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer | 113 | Thomson Reuters ONE | |
| · The primary endpoint - to show a survival advantage in the intention to treat (ITT) population - was not reached.· In a subgroup analysis, patients with low/normal baseline IL-6 and expected anti-superantigen... Mehr lesen zu: Active Biotech: Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer | ||||
